Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [31] OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY
    Visentin, A.
    Pravato, S.
    Mauro, F. R.
    Pietrasanta, D.
    Fresa, A.
    Vitale, C.
    Ciolli, S.
    Cassin, R.
    Cibien, F.
    Sportoletti, P.
    Gentile, M.
    Rigolin, G. M.
    Quaglia, F. M.
    Murru, R.
    Gozzetti, A.
    Molica, S.
    Marchetti, M.
    Scarfo, L.
    Guardalben, E.
    Avitabile, A.
    Reda, G.
    Coscia, M.
    Laurenti, L.
    Pizzolo, G.
    Semenzato, G.
    Foa, R.
    Cuneo, A.
    Trentin, L.
    HAEMATOLOGICA, 2021, 106 (10) : 62 - 63
  • [32] Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Wierda, W. G.
    Kipps, T. J.
    Duerig, J.
    Griskevicius, L.
    Stilgenbauer, S.
    Mayer, J.
    Gorczyca, M.
    Andersen, M.
    Nielsen, T.
    Russell, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Miller, Cecelia
    Lozanski, Gerard
    Little, Richard F.
    Hill, Brian T.
    Ding, Wei
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2021, 138 : 3728 - +
  • [34] Ofatumumab-Based Chemoimmunotherapy Is Effective and Well Tolerated in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Shanafelt, Tait
    Lanasa, Mark C.
    Call, Timothy G.
    Beaven, Anne W.
    Leis, Jose F.
    LaPlant, Betsy
    Bowen, Deborah
    Conte, Michael
    Jelinek, Diane F.
    Hanson, Curtis A.
    Kay, Neil E.
    Zent, Clive S.
    CANCER, 2013, 119 (21) : 3788 - 3796
  • [35] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
    Byrd, John C.
    Flynn, Joseph M.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Carlile, David J.
    Fingerle-Rowson, Guenter
    Tyson, Nicola
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2016, 127 (01) : 79 - 86
  • [36] A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Mariela, Pantoja
    Brandwein, Joseph
    Kukreti, Vishal
    Trudel, Suzanne
    Wei, Ellen
    Tong, Jieffei
    Moran, Mike
    BLOOD, 2007, 110 (11) : 608A - 608A
  • [37] A Phase II Stud of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine
    Paul, Harminder
    Xu, Wei
    Kukreti, Vishal
    Trudel, Suzanne
    Wei, Ellen
    Li, Zhi Hua
    Brandwein, Joseph
    Pantoja, Mariela
    Leung-Hagensteijn, Chungyee
    BLOOD, 2008, 112 (11) : 23 - 23
  • [38] Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia (CLL).
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 360B - 361B
  • [39] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [40] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
12345